Slope.io, Inc.

Slope. io, Inc. is a biotechnology company specializing in biospecimen lifecycle management software, enhancing the efficiency of clinical trials through precise tracking and management of biospecimens. Founded in 2016 and headquartered in Chattanooga, US, Slope.

io, Inc. provides comprehensive biospecimen management solutions. The company, co-founded by Michael Felix and Rust Felix, has secured a total of USD 20. 00 mn across three funding rounds, with the latest Seed round led by New Enterprise Associates in October 2021.

Slope has pivoted to focus on decentralized and direct-to-patient clinical trials. Slope’s core product, Biospecimen360™, offers an end-to-end biospecimen lifecycle management software that facilitates real-time tracking and management of biospecimens during clinical trials. It enhances data quality and compliance for clinical trial sponsors, research sites, and clinical research organizations (CROs), particularly within the pharmaceutical and biotechnology sectors in North America and Europe. The platform is utilized by nearly 80% of NCI-designated cancer centers, highlighting its critical role in clinical research.

Slope generates revenue primarily through subscription services related to its Biospecimen360™ platform, which includes tiered pricing for access and support. The business model is based on B2B transactions with sponsors, research sites, and CROs, who engage with Slope for advanced, customizable tech-enabled services, including professional consulting aimed at optimizing trial compliance and operations. Following the recent funding of USD 20 mn raised on October 6, 2021, Slope. io, Inc.

plans to enhance its go-to-market strategies while expanding into decentralized and direct-to-patient clinical trials. The company aims to further develop its product offerings and explore new geographic markets to strengthen its presence in the biotechnology sector.